ERYTECH to Host Second Quarter 2017 Conference Call and Business Update
ERYTECH (Paris:ERYP) (ADR:EYRYY),a clinical-stage
biopharmaceutical company developing innovative therapies by
encapsulating therapeutic drug substances inside red blood cells, today
announced that it will host a Second Quarter 2017 conference call and
webcast on
The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 54851684#:
USA: +1 6467224907 | United-Kingdom: +44 2030432440 | ||||
Switzerland: +41 225809022 | Germany: +49 69222229031 | ||||
France: +33 172001510 | Belgium: +32 24029640 | ||||
Sweden: +46 850334664 | Finland: +358 942599700 | ||||
Netherlands: +31 107138194 | Spain: +34 914142021 |
The webcast can be followed live online via the link:
http://www.anywhereconference.com?UserAudioMode=DATA&Name=&Conference=135310581&PIN=54851684
An archived replay of the call will be available for 90 days by dialing
(US &
An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at investors.erytech.com.
About ERYTECH: www.erytech.com
Founded in
Eryaspase consists of an enzyme, L-asparaginase, encapsulated inside
donor-derived red blood cells. L-asparaginase depletes asparagine, a
naturally occurring amino acid essential for the survival and
proliferation of cancer cells, from circulating blood plasma. ERYTECH
produces eryaspase at its own GMP-approved and operational manufacturing
site in
In addition to eryaspase, ERYTECH is developing two other product candidates that focus on using encapsulated enzymes to target cancer metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform to develop cancer immunotherapies and enzyme replacement therapies.
ERYTECH is listed on
Forward-looking information
This press release contains forward-looking statements, forecasts and
estimates with respect to the clinical development plans, business and
regulatory strategy, and anticipated future performance of ERYTECH and
of the market in which it operates. Certain of these statements,
forecasts and estimates can be recognized by the use of words such as,
without limitation, “believes”, “anticipates”, “expects”, “intends”,
“plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar
expressions. They include all matters that are not historical facts.
Such statements, forecasts and estimates are based on various
assumptions and assessments of known and unknown risks, uncertainties
and other factors, which were deemed reasonable when made but may or may
not prove to be correct. Actual events are difficult to predict and may
depend upon factors that are beyond ERYTECH's control. There can be no
guarantees with respect to pipeline product candidates that the
candidates will receive the necessary regulatory approvals or that they
will prove to be commercially successful. Therefore, actual results may
turn out to be materially different from the anticipated future results,
performance or achievements expressed or implied by such statements,
forecasts and estimates. Documents filed by
View source version on businesswire.com: http://www.businesswire.com/news/home/20170906005963/en/
Source: ERYTECH
ERYTECH
Gil Beyen
Chairman and CEO
Eric
Soyer
CFO and COO
+33 4 78 74 44 38
investors@erytech.com
or
The
Ruth Group
Investor relations
Lee Roth, +1 646 536
7012
lroth@theruthgroup.com
or
Media
relations
Kirsten Thomas, +1 508 280 6592
kthomas@theruthgroup.com
or
NewCap
Julien
Perez
Investor relations
Nicolas Merigeau
Media
relations
+33 1 44 71 98 52
erytech@newcap.eu